FORGE Life Science named one of 2016’s Best University Startups by the National Council of Entrepreneurial Tech Transfer (NCET2). Read more
FORGE Life Science is awarded its fourth grant from the NIH National Institute for Allergy and Infectious Disease titled, ”Sirtuin Agonists as Pan-Influenza Antivirals” (1R44AI122488-01). Read more
Mid Atlantic Bio Angels chooses FORGE Life Science for its first Closed-End Investing Pool investment. Read more
FORGE Life Science secures an in-kind services investment from ShangPharma Investment Group Limited providing FORGE medicinal chemistry and DMPK contract research services from the service division of the ShangPharma group, ChemPartner, a leading contract research organization.
FORGE Life Science Board Chairman, Thomas Shenk is keynote speaker at the BioCentury China Healthcare Summit in Shanghai, China. His talk, “Been There, Done That, Doing It Again” tells his personal story as a serial entrepreneur from ImClone Systems to FORGE Life Science.
Dr. Eain Murphy, formerly Associate Professor of Virology at the Cleveland Clinic Lerner Research Institute, joins FORGE Life Science as Head of Biology.
FORGE Life Science is awarded its third grant from the NIH National Institute for Allergy and Infectious Disease titled, “An Antiviral to Treat Progressive Multifocal Leukoencephalopathy (PML)” (1R43AI118232-01). Read more
FORGE Life Science Founders, Ileana Cristea, Emre Koyuncu, and Thomas Shenk publish their breakthrough discovery that “Sirtuins Are Evolutionarily Conserved Viral Restriction Factors”. Read more
FORGE Life Science receives JumpStart Award announced at PA BIO Life Sciences Futures annual meeting in Philadelphia, PA. Read more
FORGE Life Science featured in the Innovator’s Corner of PharmaVoice magazine. Read more
